Trigeminal Neuralgia and Microvascular Decompression

Author : Prof. Dr. Andrew J. Fishman, M.D. Board-Certified Surgeon in Otology, Neurotology, Skull Base, Head and Neck, Facial Reconstructive, and Sinonasal & Maxillary Surgery

Trigeminal neuralgia is sometimes called “the suicide disease” — a label that captures the

severity of the pain and the desperation it produces in patients who have not yet found

effective treatment. The good news is that this label belongs to a previous era. Modern

treatment of trigeminal neuralgia is highly effective, and most patients can achieve durable

pain relief through a thoughtful sequence of medical and surgical options. The patients who

continue to suffer are most often those whose diagnosis has not been correctly made, or

whose treatment has stopped short of the options that work.

What Trigeminal Neuralgia Is

Trigeminal neuralgia is a pain syndrome of the trigeminal nerve — the fifth cranial nerve,

which carries sensation from the face.

The pain has a recognizable signature:

• Sharp, electric, shock-like, or stabbing in quality — not a steady ache or pressure

• Strictly one-sided in the great majority of patients

• Located in the distribution of one or more of the three trigeminal branches — the

  forehead and eye (V1), the cheek (V2), or the jaw and chin (V3); V2 and V3 are most

  commonly affected.

• Triggered by light touch or normal activity — brushing teeth, washing the face,

  talking, chewing, a gentle breeze on the cheek.

• Brief but excruciating — individual attacks last seconds, but multiple attacks per day

  are common.

• Episodic — periods of attacks alternate with periods of relative quiet, sometimes lasting

  weeks or months.

Patients with classical trigeminal neuralgia can describe their pain very precisely once they

meet a physician who asks the right questions. The diagnosis is largely clinical. Imaging is

done not to make the diagnosis but to identify the cause and to rule out the conditions that

can mimic trigeminal neuralgia — including multiple sclerosis and tumors of the

cerebellopontine angle.

Why the Pain Occurs

In the great majority of patients with classical trigeminal neuralgia, the cause is vascular

compression of the trigeminal nerve at the point where it exits the brainstem — most

commonly by a loop of the superior cerebellar artery, less commonly by other vessels. The

vessel pulsates against the nerve over years, eroding the protective myelin coating and

allowing the nerve fibers to misfire. High-resolution MRI sequences specifically designed to

look at the relationship between the nerve and the surrounding vessels can identify this

compression in most patients.

In a smaller number of patients, the cause is something else:

• Multiple sclerosis can produce trigeminal pain that is otherwise identical to classical

  trigeminal neuralgia, through a demyelinating plaque affecting the trigeminal pathway

• Tumors of the cerebellopontine angle (vestibular schwannoma, meningioma,

  epidermoid) can present with trigeminal neuralgia

• Other compressive lesions at the skull base

  
  

Identifying the underlying cause is part of the workup of every patient with trigeminal

neuralgia, because the treatment depends on the cause.

Medical Treatment Is the First Step

The first-line treatment for trigeminal neuralgia is medical, and most patients respond well

— at least initially.

Carbamazepine is the most effective medication and remains the first-line agent. Properly

titrated to an effective dose, it produces meaningful pain relief in the majority of patients.

The challenge is that the doses needed for full effect are sometimes accompanied by side

effects (drowsiness, balance disturbance, hyponatremia), and the medication can lose

effectiveness over time in some patients.

Oxcarbazepine is a related medication with somewhat better tolerability and similar

effectiveness; it is the alternative first-line option in many practices.

Other medications used as second-line or adjunctive therapy include baclofen,

gabapentin, lamotrigine, and pregabalin. These can be useful alone or in combination with

the first-line agents.

The honest reality is that medications produce excellent initial relief in most patients, partial

relief in some, and gradually lose effectiveness in many. Patients who are doing well on a

stable medication regimen with manageable side effects do not need surgery. Patients

whose medications are losing effectiveness, who cannot tolerate the side effects, or who

have never gotten complete relief are candidates for the next step.

Procedures and Surgery

When medical management is not enough, several options exist, with very different profiles.

Diagnostic and therapeutic nerve blocks. Local anesthetic blocks of specific trigeminal

branches — performed in selected patients — can confirm the diagnosis and provide

temporary relief. In some cases, blocks combined with steroid can produce more lasting

effect. Blocks are most useful as part of the diagnostic workup and as a bridge to definitive

treatment.

Percutaneous procedures. Several procedures are performed by passing a needle through

the skin of the cheek to the trigeminal ganglion at the base of the skull and producing a

controlled injury to the nerve. These include radiofrequency thermocoagulation, glycerol

rhizolysis, and balloon compression. All produce pain relief in the majority of patients, with

the trade-off of facial numbness and somewhat shorter durability than open surgery. They

are useful in elderly patients or those with significant medical comorbidities who are not

candidates for craniotomy.

Stereotactic radiosurgery (Gamma Knife or comparable technologies) delivers a focused

dose of radiation to the trigeminal nerve at the root entry zone, producing pain relief over

weeks to months in the majority of patients. It is useful in patients who are not surgical

candidates or who prefer a non-operative approach, though it produces some degree of

facial numbness in many patients and pain relief may take time to develop.

Microvascular decompression (MVD) is the most definitive surgical treatment and is

considered the gold standard for classical trigeminal neuralgia caused by vascular

compression. The principle is direct: the responsible blood vessel is gently separated from

the trigeminal nerve under the operating microscope, and a small piece of inert material

(typically Teflon) is placed between them to prevent recompression. Because the operation

addresses the cause of the pain rather than damaging the nerve to interrupt the pain signal,

it preserves facial sensation and produces the most durable results. Initial pain relief is

achieved in roughly 85–95% of appropriately selected patients, with around 70% remaining

pain-free at ten years.

Microvascular Decompression in My Practice

MVD is a skull base operation performed through the retrosigmoid approach — a small

craniotomy behind the ear that opens a corridor into the cerebellopontine angle. The same

approach is used for vestibular schwannoma surgery, glomus tumor work, and other lateral

skull base operations. For a surgeon whose practice already includes regular operating in

this corridor, the addition of MVD is a natural extension of the same skull base technique.

The operation is performed under the operating microscope at high magnification, with

continuous neurophysiologic monitoring of the cranial nerves at risk (the trigeminal, facial,

and acoustic nerves all pass through or near this region). The preoperative imaging is

reviewed in detail — both routine MRI and the specific high-resolution sequences that show

the relationship between the trigeminal nerve and the surrounding vessels. The anatomic

plan is built before the operation begins, not improvised during it.

In selected cases — depending on the patient and the institution — MVD is performed as a

multidisciplinary procedure with neurosurgical colleagues, particularly when the patient has

additional intracranial pathology or specific anatomic considerations. The collaborative

framework is the same as the one used for pituitary and other endoscopic skull base

operations in my practice.

What Patients Should Expect

Recovery from MVD is typically faster than patients expect. The operation takes two to

three hours. The hospital stay is usually three to five days. There is a small surgical site

behind the ear, with no visible scar after the hair regrows. Most patients return to office

work within three to four weeks and to full activity within six to eight weeks. The pain relief is

usually noticed immediately on waking from surgery — many patients describe the absence

of pain as the most striking feature of the first postoperative morning.

The risks of MVD, while present, are low in experienced hands. The most common are

hearing changes (around 1–3% in published series), CSF leak (managed conservatively in

most cases), and rare cases of more significant complications. The risk profile is favorable

compared with the lifelong burden of unrelieved trigeminal neuralgia, but the decision to

proceed with surgery is always made carefully and only when the diagnosis is certain and

medical options have been adequately tried.

When to Seek a Second Opinion

If you have trigeminal neuralgia and your medications have lost effectiveness or are causing

intolerable side effects, if you have been told that nothing more can be done, if you have

been offered surgery without a detailed discussion of the alternatives, if your diagnosis has

never been confirmed with appropriate imaging, or if you have undergone a procedure that

did not produce the expected relief — a careful second opinion is reasonable and often

valuable. The right operation for the right patient at the right time produces excellent

results, but each of those qualifiers matters.